Fig. 3From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United StatesTime to progression on first line therapy with aromatase inhibitors – from chart review. Survivor function at 2 months: 0.845 / Survivor function at 3 months: 0.816 / Survivor function at 5 months: 0.747; median time to progression: 12.0 monthsBack to article page